Literature DB >> 21603970

Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities.

Vivek Bhakta Mathema1, Young-Sang Koh, Balkrishna Chand Thakuri, Mika Sillanpää.   

Abstract

Parthenolide, a naturally occurring sesquiterpene lactone derived from feverfew (Tanacetum parthenium), exhibits exceptional anti-cancer and anti-inflammatory properties, making it a prominent candidate for further studies and drug development. In this review, we briefly investigate molecular events and cell-specific activities of this chemical in relation to cytochrome c, nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB), signal transduction and activation of transcription (STAT), reactive oxygen species (ROS), TCP, HDACs, microtubules, and inflammasomes. This paper reports that parthenolide shows strong NF-κB- and STAT-inhibition-mediated transcriptional suppression of pro-apoptotic genes. This compound acts both at the transcriptional level and by direct inhibition of associated kinases (IKK-β). Similarly, this review discusses parthenolide-induced ROS-mediated apoptosis of tumor cells via the intrinsic apoptotic signaling pathway. The unique ability of this compound to not harm normal cells but at the same time induce sensitization to extrinsic as well as intrinsic apoptosis signaling in cancer cells provides an important, novel therapeutic strategy for treatment of cancer and inflammation-related disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21603970     DOI: 10.1007/s10753-011-9346-0

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  57 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  The Feverfew plant-derived compound, parthenolide enhances platelet production and attenuates platelet activation through NF-κB inhibition.

Authors:  Julie Sahler; Jamie J Bernard; Sherry L Spinelli; Neil Blumberg; Richard P Phipps
Journal:  Thromb Res       Date:  2011-01-26       Impact factor: 3.944

Review 3.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer.

Authors:  Saverio Minucci; Pier Giuseppe Pelicci
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

4.  Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis.

Authors:  A Mialhe; L Lafanechère; I Treilleux; N Peloux; C Dumontet; A Brémond; M H Panh; R Payan; J Wehland; R L Margolis; D Job
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

5.  Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation.

Authors:  Daniela Carlisi; Antonella D'Anneo; Liliana Angileri; Marianna Lauricella; Sonia Emanuele; Andrea Santulli; Renza Vento; Giovanni Tesoriere
Journal:  J Cell Physiol       Date:  2011-06       Impact factor: 6.384

6.  A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells.

Authors:  Yulan Sun; Daret K St Clair; Yong Xu; Peter A Crooks; William H St Clair
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

7.  Parthenolide inhibits tubulin carboxypeptidase activity.

Authors:  Xavier Fonrose; Frédéric Ausseil; Emmanuelle Soleilhac; Véronique Masson; Bruno David; Isabelle Pouny; Jean-Christophe Cintrat; Bernard Rousseau; Caroline Barette; Georges Massiot; Laurence Lafanechère
Journal:  Cancer Res       Date:  2007-04-01       Impact factor: 12.701

8.  Ex vivo activity of histone deacetylase inhibitors against multidrug-resistant clinical isolates of Plasmodium falciparum and P. vivax.

Authors:  Jutta Marfurt; Ferryanto Chalfein; Pak Prayoga; Frans Wabiser; Enny Kenangalem; Kim A Piera; David P Fairlie; Emiliana Tjitra; Nicholas M Anstey; Kathy T Andrews; Ric N Price
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

9.  The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.

Authors:  Yun Dai; Monica L Guzman; Shuang Chen; Li Wang; Sin-Kei Yeung; Xin-Yan Pei; Paul Dent; Craig T Jordan; Steven Grant
Journal:  Br J Haematol       Date:  2010-08-02       Impact factor: 6.998

10.  Parthenolide specifically depletes histone deacetylase 1 protein and induces cell death through ataxia telangiectasia mutated.

Authors:  Y N Vashisht Gopal; Tarandeep S Arora; Michael W Van Dyke
Journal:  Chem Biol       Date:  2007-07
View more
  52 in total

Review 1.  Development of Anticancer Agents from Plant-Derived Sesquiterpene Lactones.

Authors:  Yulin Ren; Jianhua Yu; A Douglas Kinghorn
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

2.  Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.

Authors:  Juan Yuan; Núria Llamas Luceño; Bjoern Sander; Monika M Golas
Journal:  Cell Oncol (Dordr)       Date:  2017-04-20       Impact factor: 6.730

3.  Parthenolide attenuates 7,12-dimethylbenz[a]anthracene induced hamster buccal pouch carcinogenesis.

Authors:  Nagarethinam Baskaran; Govindan Sadasivam Selvam; Subramani Yuvaraj; Albert Abhishek
Journal:  Mol Cell Biochem       Date:  2017-08-12       Impact factor: 3.396

4.  Parthenolide inhibits the proliferation and induces the apoptosis of human uveal melanoma cells.

Authors:  Song-Tian Che; Li Bie; Xu Li; Hui Qi; Peng Yu; Ling Zuo
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

5.  The Nonartemisinin Sesquiterpene Lactones Parthenin and Parthenolide Block Plasmodium falciparum Sexual Stage Transmission.

Authors:  Jared N Balaich; Derrick K Mathias; Baldwyn Torto; Bryan T Jackson; Dingyin Tao; Babak Ebrahimi; Brian B Tarimo; Xavier Cheseto; Woodbridge A Foster; Rhoel R Dinglasan
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

6.  Parthenolide Covalently Targets and Inhibits Focal Adhesion Kinase in Breast Cancer Cells.

Authors:  Charles A Berdan; Raymond Ho; Haley S Lehtola; Milton To; Xirui Hu; Tucker R Huffman; Yana Petri; Chad R Altobelli; Sasha G Demeulenaere; James A Olzmann; Thomas J Maimone; Daniel K Nomura
Journal:  Cell Chem Biol       Date:  2019-05-09       Impact factor: 8.116

7.  Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells.

Authors:  Shanshan Pei; Mohammad Minhajuddin; Angelo D'Alessandro; Travis Nemkov; Brett M Stevens; Biniam Adane; Nabilah Khan; Fred K Hagen; Vinod K Yadav; Subhajyoti De; John M Ashton; Kirk C Hansen; Jonathan A Gutman; Daniel A Pollyea; Peter A Crooks; Clayton Smith; Craig T Jordan
Journal:  J Biol Chem       Date:  2016-08-29       Impact factor: 5.157

8.  Biofilm inhibitors that target amyloid proteins.

Authors:  Diego Romero; Edgardo Sanabria-Valentín; Hera Vlamakis; Roberto Kolter
Journal:  Chem Biol       Date:  2013-01-24

9.  Activation of antioxidant response element in mouse primary cortical cultures with sesquiterpene lactones isolated from Tanacetum parthenium.

Authors:  Justin T Fischedick; Miranda Standiford; Delinda A Johnson; Ric C H De Vos; Slađana Todorović; Tijana Banjanac; Rob Verpoorte; Jeffrey A Johnson
Journal:  Planta Med       Date:  2012-08-24       Impact factor: 3.352

10.  Parthenolide induces apoptosis by activating the mitochondrial and death receptor pathways and inhibits FAK-mediated cell invasion.

Authors:  Sang Won Kwak; Eon Sub Park; Chung Soo Lee
Journal:  Mol Cell Biochem       Date:  2013-09-25       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.